Seer, Inc. (SEER) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
SEER (SEER) Q1 2026: Operating Expenses Drop 20% as Biobank Momentum Builds
May 14, 2026
-
SEER (SEER) Q4 2025: Installed Base Jumps 67% as Proteograph Adoption Outpaces Funding Headwinds
February 27, 2026
-
SEER (SEER) Q3 2025: Instrument Shipments Triple, Academic Uptake Surges Despite Funding Headwinds
November 07, 2025
-
SEER (SEER) Q2 2025: ProteoGraph 1 Launch Doubles Throughput, Unlocks 20,000-Sample Population Studies
August 07, 2025